191 related articles for article (PubMed ID: 23567045)
1. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma.
Zhang M; Zhou X; Wang B; Yung BC; Lee LJ; Ghoshal K; Lee RJ
J Control Release; 2013 Jun; 168(3):251-61. PubMed ID: 23567045
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of microRNA 146b mimic to hepatocytes by lactosylated PDMAEMA nanoparticles for the treatment of NAFLD.
He S; Guo W; Deng F; Chen K; Jiang Y; Dong M; Peng L; Chen X
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):217-228. PubMed ID: 29560749
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma.
Thao LQ; Lee C; Kim B; Lee S; Kim TH; Kim JO; Lee ES; Oh KT; Choi HG; Yoo SD; Youn YS
Colloids Surf B Biointerfaces; 2017 Apr; 152():183-191. PubMed ID: 28110040
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
5. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-Assisted miR-122-Loaded Polymeric Nanodroplets for Hepatocellular Carcinoma Gene Therapy.
Guo H; Xu M; Cao Z; Li W; Chen L; Xie X; Wang W; Liu J
Mol Pharm; 2020 Feb; 17(2):541-553. PubMed ID: 31876426
[TBL] [Abstract][Full Text] [Related]
7. Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma.
Teran-Saavedra NG; Sarabia-Sainz JA; Silva-Campa E; Burgara-Estrella AJ; Guzmán-Partida AM; Ramos-Clamont Montfort G; Pedroza-Montero M; Vazquez-Moreno L
Molecules; 2019 Apr; 24(7):. PubMed ID: 30970533
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.
Zhang W; Peng F; Zhou T; Huang Y; Zhang L; Ye P; Lu M; Yang G; Gai Y; Yang T; Ma X; Xiang G
Int J Nanomedicine; 2015; 10():4825-36. PubMed ID: 26251599
[TBL] [Abstract][Full Text] [Related]
9. Lactosylated PLGA nanoparticles containing ϵ-polylysine for the sustained release and liver-targeted delivery of the negatively charged proteins.
Zhou P; An T; Zhao C; Li Y; Li R; Yang R; Wang Y; Gao X
Int J Pharm; 2015 Jan; 478(2):633-43. PubMed ID: 25510599
[TBL] [Abstract][Full Text] [Related]
10. Comparative biodistribution in mice of cyanine dyes loaded in lipid nanoparticles.
Mérian J; Boisgard R; Bayle PA; Bardet M; Tavitian B; Texier I
Eur J Pharm Biopharm; 2015 Jun; 93():1-10. PubMed ID: 25805562
[TBL] [Abstract][Full Text] [Related]
11. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo gene delivery mediated by Lactosylated dendrimer/alpha-cyclodextrin conjugates (G2) into hepatocytes.
Arima H; Yamashita S; Mori Y; Hayashi Y; Motoyama K; Hattori K; Takeuchi T; Jono H; Ando Y; Hirayama F; Uekama K
J Control Release; 2010 Aug; 146(1):106-17. PubMed ID: 20678990
[TBL] [Abstract][Full Text] [Related]
13. Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease.
Fan N; Zhao J; Zhao W; Zhang X; Song Q; Shen Y; Shum HC; Wang Y; Rong J
J Control Release; 2022 Jul; 347():44-54. PubMed ID: 35483638
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of microRNA-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice.
Varshney A; Panda JJ; Singh AK; Yadav N; Bihari C; Biswas S; Sarin SK; Chauhan VS
Hepatology; 2018 Apr; 67(4):1392-1407. PubMed ID: 29108133
[TBL] [Abstract][Full Text] [Related]
15. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Gu J; Al-Bayati K; Ho EA
Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
[TBL] [Abstract][Full Text] [Related]
16. AntihypoxamiR functionalized gramicidin lipid nanoparticles rescue against ischemic memory improving cutaneous wound healing.
Ghatak S; Li J; Chan YC; Gnyawali SC; Steen E; Yung BC; Khanna S; Roy S; Lee RJ; Sen CK
Nanomedicine; 2016 Oct; 12(7):1827-1831. PubMed ID: 27033464
[TBL] [Abstract][Full Text] [Related]
17. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab')
Jin C; Bai L; Lin L; Wang S; Yin X
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1076-1084. PubMed ID: 28776396
[TBL] [Abstract][Full Text] [Related]
19. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
[TBL] [Abstract][Full Text] [Related]
20. Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery.
Quan G; Pan X; Wang Z; Wu Q; Li G; Dian L; Chen B; Wu C
J Nanobiotechnology; 2015 Feb; 13():7. PubMed ID: 25643602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
